/ /

  • linkedin
  • Increase Font
  • Sharebar

    How the Japanese treat allergic conjunctivitis

    Though allergens and environment may differ, treatments similar to those in U.S.

     

    Getting treatment results

    Although the Japanese classification system bears resemblance to how ophthalmology and optometry bracket these disease states in the U.S., the treatment patterns illustrate divergence likely due to drug availability and guidelines.8

    Table 1.

    As with any management paradigm, therapeutics precedes surgical intervention to minimize the risk profile.

    Related: The increasing role of climate, hygiene, and aerobiology in allergy

    The medical decision path from mast cell, to antihistamine H1 antagonists/combinations, to steroid application remains the same no matter where you reside (Table 1).4 In managing pediatric patients or those with corneal epithelial defects from vernal or atopic keratoconjunctivitis, oral medication is dispensed with a one- to two-week follow-up and close communication among ophthalmology, internists, and pediatricians to watch for side effects.

    The course of action diverges when handling recalcitrant cases in which these therapeutic remedies are not exerting the desired effect. When this situation arises, subtarsal conjunctival steroid injections of triamcinolone acetonide or betamethasone are administered to the upper eyelid for intractable or severe cases with cautionary notes to follow carefully for intraocular pressure elevation or repeated use in children under age 10.9,10

    While cyclosporine (Papilock 0.1 percent, Santen Pharmaceutical Co.) solution and tacrolimus (Talymus 0.1 percent, Senju Pharmaceutical Co.) suspension are reserved for experimental literature work and off-label clinical usage, Japan has approved these agents for VKC treatment to reduce the need for long-term steroid use.11

    Further surgical management is warranted when symptoms are not alleviated by drug treatment and/or conjunctival papillary hyperplasia progresses, causing refractory corneal epithelium disorder. The procedure performed is a tarsal conjunctival resection including the papillae to reduce the mechanical and biological burden on the ocular surface.4 Even though the treatment result is immediate, there can be recurrence of conjunctival papillary hyperplasia in some cases.

    U.S. is no different

    Treatment and management methodology in Japan do not digress tremendously from the American Academy of Ophthalmology preferred practice guidelines for conjunctivitis.12

    The moral of the story is we are not so different after all.

     

    References

    1. Kaneko, Y., Motohashi, Y., Nakamura, H., Endo T, Eboshida A. Increasing Prevalence of Japanese Cedar Pollinosis: A Meta-Regression Analysis. Int Arch Allergy Immunol. 2005; 136:365–371.

    2. Okamoto Y, Horiguchi S, Yamamoto H, Yonekura S, Hanazawa T. Present situation of cedar pollinosis in Japan and its immune responses. Allergol Int. 2009; Jun 58(2): 155–162.

    3. Makihara S, Okano M, Fujiwara T, Kimura M, Higaki T, Haruna T, Noda Y, Kanai K, Kariya S, Nishizaki K. Early interventional treatment with intranasal mometasone furoate in Japanese cedar/cypress pollinosis: a randomized placebo-controlled trial. Allergol Int. 2012 Jun;61(2):295-304.

    4. Takamura E, Uchio E, Ebihara N, Ohno S, Ohashi Y, Okamoto S, Kumagai N, Satake Y, Shoji J, Nakagawa Y, Namba K, Fukagawa K, Fukushima A, Fujishima H; Japanese Society of Allergology. Japanese guidelines for allergic conjunctival diseases 2017. Allergol Int. 2017 Apr;66(2):220-229.

    5. Asthma and Allergy Foundation of America. Allergy Facts and Figures. Available at: http://www.aafa.org/display.cfm?id=9&sub=30. Accessed 1/10/18.

    6. Cooper MS. 3 Tips for Discussing Allergy with Kids. Optometry Times. Available at: http://optometrytimes.modernmedicine.com/optometrytimes/news/3-tips-navigate-allergy-discussion-kids?page=full. Accessed 1/10/18.

    7. Japanese Ocular Allergology Society. [Guidelines for the clinical management of allergic conjunctival disease (2nd edition)]. Nippon Ganka Gakkai Zasshi. 2010 Oct;114(10):831-70.

    8. Ohno S, Uchio E, Ishizaki M, et al. [New clinical evaluation standard and seriousness classification of allergic conjunctival diseases]. Iyaku Journal [Medicine & Drug Journal]. 2001; 37:1341–1349. (in Japanese).

    9. Kumar S. Vernal keratoconjunctivitis: a major review. Acta Ophthalmol. 2009 Mar;87(2):133-47.

    10. De Smedt S, Wildner G, Kestelyn P. Vernal keratoconjunctivitis: an update. Br J Ophthalmol. 2013 Jan;97(1):9-14.

    11. Ohashi Y, Ebihara N, Fujishima H, Fukushima A, Kumagai N, Nakagawa Y, Namba K, Okamoto S, Shoji J, Takamura E, Hayashi K. A randomized, placebo-controlled clinical trial of tacrolimus ophthalmic suspension 0.1% in severe allergic conjunctivitis. J Ocul Pharmacol Ther. 2010 Apr; 26(2):165–174. J Ocul Pharmacol Ther. 2010 Apr;26(2):165-74.

    12. AAO Cornea/External Disease PPP Panel, Hoskins Center for Quality Eye Care. Conjunctivitis PPP - 2013. American Academy of Ophthalmology. Available at: https://www.aao.org/preferred-practice-pattern/conjunctivitis-ppp--2013. Accessed 1/10/17.

    Read more from Dr. Cooper here

    Michael S. Cooper, OD
    Michael S. Cooper, OD, is in private practice in Willimantic, CT. He is a consultant to Allergan, BioTissue, Johnson & Johnson Vision ...

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Optometry Times A/V